GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » ROC (Joel Greenblatt) %

Marizyme (Marizyme) ROC (Joel Greenblatt) % : -711.91% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Marizyme's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -711.91%.

The historical rank and industry rank for Marizyme's ROC (Joel Greenblatt) % or its related term are showing as below:

MRZM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2662.45   Med: -1729.84   Max: -437.74
Current: -2662.45

During the past 13 years, Marizyme's highest ROC (Joel Greenblatt) % was -437.74%. The lowest was -2662.45%. And the median was -1729.84%.

MRZM's ROC (Joel Greenblatt) % is ranked worse than
79.6% of 1461 companies
in the Biotechnology industry
Industry Median: -318.79 vs MRZM: -2662.45

Marizyme's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Marizyme ROC (Joel Greenblatt) % Historical Data

The historical data trend for Marizyme's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme ROC (Joel Greenblatt) % Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -437.74 -870.80 -2,588.88 -2,626.02

Marizyme Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,394.71 -231.31 -2,111.29 -7,957.11 -711.91

Competitive Comparison of Marizyme's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Marizyme's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Marizyme's ROC (Joel Greenblatt) % falls into.



Marizyme ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.043 + 0.099 + 0.661) - (2.324 + 0 + 25.555)
=-27.076

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.06 + 0.025 + 0.7) - (2.447 + 0 + 0.106)
=-1.768

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Marizyme for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.276/( ( (1.211 + max(-27.076, 0)) + (1.114 + max(-1.768, 0)) )/ 2 )
=-8.276/( ( 1.211 + 1.114 )/ 2 )
=-8.276/1.1625
=-711.91 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marizyme  (OTCPK:MRZM) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Marizyme ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Marizyme's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme (Marizyme) Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478